This metaanalysis suggests a benefit of metformin in men with diabetes and prostate cancer. Pancreatic cancer, metformin, diabetes mellitus, type 2, meta analysis. The random effects metaanalysis showed that the use of metformin was associated with a significant reduction in the risk of cancer of the oesophagus or 0. Meta analysis found metformin therapy was associated with decreased risk for colorectal adenomas and colorectal cancer among t2 patients. An electronic search was conducted using pubmed, embase, and web of science. Metformin improves overall survival of colorectal cancer patients with diabetes. Pubmed, embase, and the cochrane library databases were searched for observational studies. Metformin improves overall survival of colorectal cancer. This metaanalysis was performed to provide the evidence of clinical efficacy and safety of metformin in t1dm. Metformin x breastcancer x diabetesmellitus x survival x meta analysis abstract background.
Metformin can reduce the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of overall cancer, liver cancer and breast cancer. We performed a comprehensive literature search and meta. Relationship of metformin with the risk of pancreatic. Seven cohort studies were included in our analysis. Relationship of metformin with the risk of pancreatic cancer in patients with type 2 diabetes.
Abstract previous metaanalyses have shown that the antidiabetic agent metformin is associated with reduced cancer incidence and mortality. Cancer risk associated with use of metformin and sulfonylurea. Revman and comprehensive metaanalysis software has used, if needed. The relationship between prostate cancer and metformin. Metformin, an insulinlowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. Reduced colorectal cancer incidence in type 2 diabetic. The pleiotropic anticancer effects of mtf on cancer cells have not been fully explored yet. However, the association between metformin use and the incidence and survival of. The 7 studies were all cohort studies, most of which were publishedwithin5years. In light of the exploding global epidemic of diabetes, there is a pressing need for implementing diabetes treatment with potentially protective. Metaanalysis suggests benefits of metformin therapy in patients with comorbid kidney or heart disease. A recent metaanalysis concluded that metformin decreased gc risk by 24%, but there was a statistically significant heterogeneity among studies.
Monotherapy with metformin versus sulfonylureas and risk of. Given the retrospective nature of most studies and the possibility that the control treatments increase risk, phase ii trials are needed before large cancer prevention trials are launched. By interrogating the gene expression omnibus geo for microarray expression data, we identified eight eligible submissions, representing five different studies, that employed various conditions. Furthermore, a metaanalysis evaluating the effect of metformin among diabetic subjects with any type of cancer showed that metformin use was associated with improved os.
Previous meta analyses have shown that the antidiabetic agent metformin is associated with reduced cancer incidence and mortality. However, this effect has not been consistently demonstrated in animal models and recent epidemiologic studies. Metformin use is associated with reduced incidence and. The os meta analysis was performed following the appropriate cochrane guidelines 22. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome. Can metformin prevent colorectal cancer for type 2 patients. The effect of metformin therapy on incidence and prognosis in. A comprehensive literature search was performed using pubmed, embase, and the cochrane central search library in december 2017. However, findings regarding breast cancer have been mixed. All statistical analyses were conducted using stata software version. The metaanalysis was performed on 6 studies of a total of 1,579 metformin users with lung cancer.
Cohort or case control studies of metformin and risk of pancreatic cancer in patients with type 2 diabetes mellitus were included. Effect of metformin on allcause and cardiovascular. Research paper the clinical effect of metformin on the. The aim of the study was to evaluate the association between metformin use and cancer incidence and mortality in diabetic patients.
Metformin might modulate the clinical outcomes of diabetic cancer patients. Our metaanalysis indicated that metformin was negatively associated with the incidence of overall cancer, liver. However, the association between metformin use and the incidence and survival of endometrial cancer ec remains controversial. However, metformin could prolong the overall survival of patients with ec and reduce their risk of cancer. Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent. Our meta analysis revealed that diabetic cancer patients who were treated with metformin demonstrated a significantly reduced risk of csm compared with those who did not receive metformin randomeffects model, pooled hr 0. The relationship between prostate cancer and metformin consumption.
Metformin, an antidiabetic drug, has emerged as a new adjunctive strategy for different cancer types, including endometrial cancer. Results of the metaanalysis showed that the incident cancer risks were. However, further carefully designed studies are needed to confirm findings and to assess. For each metaanalysis on the association between metformin use and cancer risk or survival outcomes, the summary effect was synthesized. Effects of metformin treatment on radiotherapy efficacy in patients with cancer and diabetes. All analyses were performed with sas software version 8. We performed a meta analysis with a focus on confounders and biases, including body mass index bmi, study type, and timerelated biases. In the same metaanalysis, metformin use was associated with signifi cantly reduced allcause mortality hr 0. Apr 18, 2018 previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer ec, while the results have been inconsistent. This study showed that metformin use was significantly associated with a decreased. This metaanalysis did not prove that metformin was beneficial for preventing ec. A recent meta analysis concluded that metformin decreased gc risk by 24%, but there was a statistically significant heterogeneity among studies. Our metaanalysis indicated that there was no association of metformin use with prostate cancer risk, which further enriched the knowledge of relationship between metformin therapy and cancer development.
Endometrial carcinoma was indeed one of the neoplasms in which metformin use has been reported to correlate with potentially beneficial clinical outcomes. Recent clinical trials indicated that metformin intake might play a protective role in the incidence and oncologic outcomes of various cancers. We conducted a comprehensive literature search for all pertinent studies addressing metformin use and. The aim of the study was to evaluate the association between metformin use and cancer incidence and mortality in patients with diabetes. However, the current evidence in observational studies is. This meta analysis did not prove that metformin was beneficial for preventing ec. Cancer risk in diabetic patients treated with metformin. Metformin cancer meta analysis email protected by start bootstrap people usually get sick 12 hours to three days after they eat something contaminated. Observational studies have suggested that metformin decreases the incidence of several common cancers. Effects of metformin treatment on radiotherapy efficacy in. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes. The present large meta analysis of cohort studies did not find an association between metformin use and prostate cancer risk. Efficacy and safety of metformin for patients with type 1. Effects of metformin on survival outcomes of pancreatic.
Jul 31, 2012 observational studies have suggested that metformin decreases the incidence of several common cancers. All statistical tests were conducted using stata software version 12. Metformin inhibits stromal aromatase expression and tumor. More importantly, other important risk factors of gc including h. Previous metaanalyses have shown that the antidiabetic agent metformin is associated with reduced cancer incidence and mortality. Association of metformin intake with bladder cancer risk and. Our findings, on the protective effect of metformin, confirm the findings reported in a previous meta. Methodsprincipal findings we performed a search of medline, embase, isi web of science, cochrane library, and clinicaltrials. Background a growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Metformin use is associated with better survival of breast.
Association of the metformin with the risk of lung cancer. The beneficial effects of metformin on cancer prevention and. No beneficial effect on prostate cancer incidence was found for meformin intake in the meta analysis. The inclusion criteria of an eligible study in the metaanalysis are as follows. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of anysite and sitespecific cancers in patients with diabetes. We performed a comprehensive literature search and meta analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using pubmed, isi web of science, embase, and the cochrane library until may 2009.
Metformin therapy and risk of cancer in patients with type 2. However, metformin could prolong the overall survival of patients with ec and reduce their risk of cancer relapse. Our meta analysis evaluates whether metformin would affect the prognosis of diabetic colorectal cancer patients. Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. However, further carefully designed studies are needed to confirm findings and to assess potential generalization to nondiabetic, nonwhite, and less aggressively treated men with prostate cancer. Association of metformin with breast cancer incidence and. We performed a meta analysis to investigate the association between metformin intake and bladder cancer risk as well as oncologic outcomes in diabetes mellitus dm patients. Studies have suggested that metformin can potentially decrease the incidence of cancer and improve survival outcomes. Hong hu 1, yong fang 2, xiaoyun zhou 1, liu gong1, lili liu2, wei wang2, jiping sun 1. However, this effect has not been consistently demonstrated in animal models and recent epidemiological studies. Furthermore, a meta analysis evaluating the effect of metformin among diabetic subjects with any type of cancer showed that metformin use was associated with improved os. The effect of metformin therapy on incidence and prognosis in prostate cancer. Metformin is a safe, effective and welltolerated agent, which is recommended as the first line oral hypoglycemic in treatment of newly diagnosed type ii diabetes.
Relationship of metformin with the risk of pancreatic cancer. Monotherapy with metformin versus sulfonylureas and risk of cancer in. Metformin use and gastric cancer risk in diabetic patients. The search was carried out on observational studies and trials, without language restrictions. Effect of metformin on allcause and cardiovascular mortality. Studies have suggested that patients with type 2 diabetes may.
Metformin versus sulfonylurea in breast cancer risk of diabetic patients. Metformin treatment reduces the risk of pancreatic cancer in patients with type 2 diabetes. The metaanalysis was conducted in accordance with the guidelines for the metaanalysis of observational studies in epidemiology moose and the prisma statement. Monotherapy with metformin versus sulfonylureas and risk. Metaanalysis of microarray expression studies on metformin. Obesity and type ii diabetes are linked to increased breast cancer risk in postmenopausal women. Studies have suggested that patients with type 2 diabetes may be at an increased risk for developing colorectal cancer crc. Endometrial cancer, metformin, risk, prognosis, meta analysis background endometrial cancer ec, a tumor originating from the. Impact of metformin on clinical outcomes among men with.
The relationship between metformin use and the risk of prostate cancer is still inconclusive. Metformin mtf is derived from the legume galega officinalis, and is approved by the fda for the treatment of type 2 diabetes t2d 1,2. The purpose of this study was to investigate the relationship between prostate cancer and metformin consumption in men. Results of the meta analysis showed that the incident cancer risks were significantly decreased for cancers of the lung in metformin users, compared with non metformin users or0. Metformin use is associated with reduced incidence and improved.
Original article the effects of metformin on ovarian cancer. Our metaanalysis revealed that diabetic cancer patients who were treated with metformin demonstrated a significantly reduced risk of csm compared with those who did not receive metformin. In this metaanalysis of cohort studies and rcts investigating metformin in patients with pancreatic cancer, we demonstrated that metformin significantly benefited patients with pancreatic cancer. The metaanalysis was conducted in accordance with the guidelines for. The meta analysis was performed on 6 studies of a total of 1,579 metformin users with lung cancer. In the mean time longterm rcts are called for to confirm the clinical benefit of metformin. One of the main effects of mtf in diabetic patients is to lower. Metformin is associated with a decreased risk of cancer incidence compared with other treatments among diabetic patients. Effect of metformin on mortality among diabetic cancer.
Several studies have demonstrated that metformin mtf acts with variable efficiency as an anticancer agent. Effect of metformin on mortality among diabetic cancer patients. Preclinical data suggest that metformin may reduce breast cancer incidence and improve cancer prognosis. This meta analysis suggests a benefit of metformin in men with diabetes and prostate cancer. Metformin therapy and risk of cancer in patients with type.
Association of metformin intake with bladder cancer risk. Relevant studies reported before october 2018 was retrieved from databases including pubmed, embase. The uk prospective diabetes study ukpds 34 involved two independent investigational trials metformin vs. Meta analysis suggests benefits of metformin therapy in patients with comorbid kidney or heart disease. The meta analysis was conducted in accordance with the guidelines for the meta analysis of observational studies in epidemiology moose and the prisma statement 18, 19. Association of metformin use with cancer incidence and. We conducted searches of pubmed, embase and the cochrane central register of controlled trials to identify studies evaluating risk or survival data of ovarian cancer in diabetic patients taking metformin versus those not. Metformin is the most widely prescribed drug to lower glucose and has a definitive effect on the cardiovascular system. We found that the metformin group has a prolonged os over nonusers with a pooled hr of 0.
1418 261 316 1423 301 929 1275 1106 308 175 3 1121 247 1390 656 86 1500 738 1030 214 1071 600 223 917 843 157 795 864 1166 1498 474 1425 526